Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes.

Carcinogenesis 2018 12;39(12):1447-1454

Department of Oncology, Wayne State University, Detroit, MI, USA.

Immunotherapy is a promising advancement in the treatment of non-small-cell lung carcinoma (NSCLC), although much of how lung tumors interact with the immune system in the natural course of disease remains unknown. We investigated the impact of the expression of immune-centric genes and pathways in tumors on patient survival to reveal novel candidates for immunotherapeutic research. Tumor transcriptomes and detailed clinical characteristics were obtained from patients with NSCLC who were participants of either the Inflammation, Health and Lung Epidemiology (INHALE) (discovery, N = 280) or The Cancer Genome Atlas (TCGA) Lung (replication, N = 1026) studies. Expressions of 2253 genes derived from 48 major immune pathways were assessed for association with patient prognosis using a multivariable Cox model and pathway effects were assessed with an in-house implementation of the Gene Set Enrichment Analysis (GSEA) algorithm. Prognosis-guided gene and pathway analysis of immune-centric expression in tumors revealed significant survival enrichments across both cohorts. The 'Interleukin Signaling' pathway, containing 430 genes, was found to be statistically and significantly enriched with prognostic signal in both the INHALE (P = 0.008) and TCGA (P = 0.039) datasets. Subsequent leading-edge analysis identified a subset of genes (N = 23) shared between both cohorts, driving the pathway enrichment. Cumulative expression of this leading-edge gene signature was a strong predictor of patient survival [discovery: hazard ratio (HR) = 1.59, P = 3.0 × 10-8; replication: HR = 1.29, P = 7.4 × 10-7]. These data demonstrate the impact of immune-centric expression on patient outcomes in NSCLC. Furthermore, prognostic gene effects were localized to discrete immune pathways, of which Interleukin Signaling had the greatest impact on overall survival and the subset of genes driving these effects have promise for future therapeutic intervention.

Download full-text PDF

Publisher Site Listing
December 2018
26 Reads

Publication Analysis

Top Keywords

patient outcomes
interleukin signaling
immune-centric expression
patient survival
immune pathways
subset genes
replication 1026
10-8 replication
lung replication
atlas tcga
tcga lung
signaling' pathway
159 10-8
studies expressions
genes derived
hazard ratio
derived major
major immune


(Supplied by CrossRef)
Cancer statistics, 2018
Siegel et al.
CA. Cancer J. Clin 2018
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers et al.
Genome Med 2017
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Rizvi et al.
Science 2015
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil et al.
Nat. Rev. Clin. Oncol 2016
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
Director’s Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma et al.
Nat. Med 2008
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer et al.
Nat. Med 2002
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer
Zhu et al.
J. Clin. Oncol 2010
The prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles et al.
Nat. Med 2015
Risk of lung cancer associated with COPD phenotype based on quantitative image analysis
Schwartz et al.
Cancer Epidemiol. Biomarkers Prev 2016
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data
Cerami et al.
Cancer Discov 2012
Comprehensive genomic characterization of squamous cell lung cancers
Cancer Genome Atlas Research Network et al.
Nature 2012

Similar Publications